Aim: Given that astragaloside-IV (As-IV) has the ability to promote osteogenic differentiation, its mechanism is worthy of exploration. Methods: The effect of As-IV on rat tibial defects was examined by histopathological staining and MiR-CT scan. The alkaline phosphatase (ALP) content, osteogenic differentiation-related gene expressions, and mineralized nodule formation in bone marrow mesenchymal stem cells (BMSCs) were detected. Results: As-IV repaired tibial defects of rats. As-IV or neuromedin receptor 2 (NMUR2) overexpression elevated ALP content, mineralized nodules, osteogenic differentiation-related genes, β-catenin and NMUR2 levels, the effects of which were reversed by NMUR2 silencing or Wnt/β-catenin pathway inhibitors. Conclusion: As-IV regulates the Wnt/β-catenin pathway through NMUR2 to promote the repair of tibial defects in rats and the differentiation of BMSCs into osteoblasts.
{"title":"Astragaloside-IV induces the differentiation of bone marrow mesenchymal stem cells into osteoblasts through <i>NMUR2</i>-mediated Wnt/β-catenin pathway.","authors":"Yujing Cao, Qiuxia Lv, Zhihui Huang, Yang Li","doi":"10.2217/rme-2022-0184","DOIUrl":"https://doi.org/10.2217/rme-2022-0184","url":null,"abstract":"<p><p><b>Aim:</b> Given that astragaloside-IV (As-IV) has the ability to promote osteogenic differentiation, its mechanism is worthy of exploration. <b>Methods:</b> The effect of As-IV on rat tibial defects was examined by histopathological staining and MiR-CT scan. The alkaline phosphatase (ALP) content, osteogenic differentiation-related gene expressions, and mineralized nodule formation in bone marrow mesenchymal stem cells (BMSCs) were detected. <b>Results:</b> As-IV repaired tibial defects of rats. As-IV or neuromedin receptor 2 (<i>NMUR2</i>) overexpression elevated ALP content, mineralized nodules, osteogenic differentiation-related genes, β-catenin and <i>NMUR2</i> levels, the effects of which were reversed by <i>NMUR2</i> silencing or Wnt/β-catenin pathway inhibitors. <b>Conclusion:</b> As-IV regulates the Wnt/β-catenin pathway through <i>NMUR2</i> to promote the repair of tibial defects in rats and the differentiation of BMSCs into osteoblasts.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"471-485"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10044401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kyungje Sung, Kevin Zheng, Chris Williams, David Cunningham, Walter I Sussman
A variety of intra-articular injections are used for the management of osteoarthritis. A rare complication of intra-articular injections is acute pseudoseptic arthritis, which mimics true septic arthritis. To the authors knowledge, pseudosepsis has not been reported as a complication after platelet-rich plasma (PRP) injections. We present a case report of pseudoseptic arthritis resulting in acute postinjection pain and a joint effusion after an intra-articular PRP injection into the knee. Clinically, pseudosepsis can occur after PRP treatment with significantly elevated white blood cell counts in the synovial fluid, and should be a consideration in cases of post-PRP injection flares.
{"title":"Pseudoseptic reaction to an intra-articular platelet-rich plasma injection into the knee: a case report.","authors":"Kyungje Sung, Kevin Zheng, Chris Williams, David Cunningham, Walter I Sussman","doi":"10.2217/rme-2022-0216","DOIUrl":"https://doi.org/10.2217/rme-2022-0216","url":null,"abstract":"<p><p>A variety of intra-articular injections are used for the management of osteoarthritis. A rare complication of intra-articular injections is acute pseudoseptic arthritis, which mimics true septic arthritis. To the authors knowledge, pseudosepsis has not been reported as a complication after platelet-rich plasma (PRP) injections. We present a case report of pseudoseptic arthritis resulting in acute postinjection pain and a joint effusion after an intra-articular PRP injection into the knee. Clinically, pseudosepsis can occur after PRP treatment with significantly elevated white blood cell counts in the synovial fluid, and should be a consideration in cases of post-PRP injection flares.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"455-459"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9678678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in February 2023.
根据公开信息和非学术机构的新闻稿汇编的干细胞研究和再生医学领域的最新进展。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in February 2023.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.2217/rme-2023-0053","DOIUrl":"https://doi.org/10.2217/rme-2023-0053","url":null,"abstract":"Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in February 2023.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"443-453"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9663016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To develop a simple clinical decision rule (CDR) to identify people with knee osteoarthritis who are likely or unlikely to benefit from bone marrow aspirate concentrate (BMAC) injection. Materials & methods: A total of 92 people with clinical and radiographic evidence of refractory knee osteoarthritis received a single intra-articular (IA) BMAC injection. Multiple logistic regression analysis was used to determine which combination of risk factors predicted BMAC responsiveness. A responder was defined as a person whose knee pain improved more than 15% from baseline 6 months post procedure. Results: The CDR demonstrated that those with lower pain levels, or high pain levels with previous surgery, could be predicted to benefit from a single IA BMAC injection. Conclusion: A simple CDR containing three variables predicted responsiveness to a single IA knee BMAC injection with high accuracy. Further validation of the CDR is required prior to routine use in clinical practice.
{"title":"Derivation of a clinical decision rule for a bone marrow aspirate concentrate injection in knee osteoarthritis.","authors":"Ashley D Smith, Dasan Sydora, Robert Burnham","doi":"10.2217/rme-2023-0014","DOIUrl":"https://doi.org/10.2217/rme-2023-0014","url":null,"abstract":"<p><p><b>Aim:</b> To develop a simple clinical decision rule (CDR) to identify people with knee osteoarthritis who are likely or unlikely to benefit from bone marrow aspirate concentrate (BMAC) injection. <b>Materials & methods:</b> A total of 92 people with clinical and radiographic evidence of refractory knee osteoarthritis received a single intra-articular (IA) BMAC injection. Multiple logistic regression analysis was used to determine which combination of risk factors predicted BMAC responsiveness. A responder was defined as a person whose knee pain improved more than 15% from baseline 6 months post procedure. <b>Results:</b> The CDR demonstrated that those with lower pain levels, or high pain levels with previous surgery, could be predicted to benefit from a single IA BMAC injection. <b>Conclusion:</b> A simple CDR containing three variables predicted responsiveness to a single IA knee BMAC injection with high accuracy. Further validation of the CDR is required prior to routine use in clinical practice.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"461-470"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9678696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brandon Goodwin, Nicholas Averell, Usmaan Al-Shehab, Akhmad Ernazarov, Lisa Price, Akhil Choudhary, Richard Jermyn
Aim: We aimed to expound upon previous research examining the effect of platelet rich plasma in the treatment of sacroiliac joint (SIJ) dysfunction and pain. Materials & methods: A systematic review was employed in conjunction with a pooled analysis of the efficacy of platelet-rich plasma (PRP) in SIJ dysfunction and pain. Results: A total of 259 articles were retrieved following database systematic review. As a result, four clinical trials and two case studies were subjected to full text appraisal. The dates of publication ranged from 2015 to 2022. Conclusion: Although a unique modality, there is not enough evidence to support the employment of PRP injections over current steroid standard of care. Further double-blinded, randomized control trials are required to elucidate PRP role in SIJ dysfunction.
{"title":"Efficacy of platelet-rich plasma for sacroiliac joint dysfunction: a qualitative systematic review with pooled analysis.","authors":"Brandon Goodwin, Nicholas Averell, Usmaan Al-Shehab, Akhmad Ernazarov, Lisa Price, Akhil Choudhary, Richard Jermyn","doi":"10.2217/rme-2022-0211","DOIUrl":"https://doi.org/10.2217/rme-2022-0211","url":null,"abstract":"<p><p><b>Aim:</b> We aimed to expound upon previous research examining the effect of platelet rich plasma in the treatment of sacroiliac joint (SIJ) dysfunction and pain. <b>Materials & methods:</b> A systematic review was employed in conjunction with a pooled analysis of the efficacy of platelet-rich plasma (PRP) in SIJ dysfunction and pain. <b>Results:</b> A total of 259 articles were retrieved following database systematic review. As a result, four clinical trials and two case studies were subjected to full text appraisal. The dates of publication ranged from 2015 to 2022. <b>Conclusion:</b> Although a unique modality, there is not enough evidence to support the employment of PRP injections over current steroid standard of care. Further double-blinded, randomized control trials are required to elucidate PRP role in SIJ dysfunction.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"505-514"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9690830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Gholamalizadeh, Sajed Nazifkerdar, Nasim Safdarian, Aida Eyvaz Ziaee, Hamid Mobedi, Reza Rahbarghazi, Mehdi Khanmohammadi, Sepideh Saghati
Abnormal craniofacial bone fusion can lead to the generation of several congenital malformations such as cleft palate, craniosynostosis and craniofacial skeletal hypoplasia, which physically and mentally affect patients. Conventional approaches for the treatment of craniofacial malformations such as the transplantation of autologous bone grafts are not completely efficient and usually, patients suffer from various complications. In line with these statements, the advent of novel therapeutic approaches in human medicine is mandatory. Regarding the extent, size and severity of the bone malformation, supplementation and release of oxygen molecules into the affected sites are critical issues for successful osteogenesis. Here, tissue engineering modalities associated with oxygen supplementation and novel approaches associated with hydrogel synthesis were highlighted in terms of craniofacial malformations.
{"title":"Critical elements in tissue engineering of craniofacial malformations.","authors":"Ali Gholamalizadeh, Sajed Nazifkerdar, Nasim Safdarian, Aida Eyvaz Ziaee, Hamid Mobedi, Reza Rahbarghazi, Mehdi Khanmohammadi, Sepideh Saghati","doi":"10.2217/rme-2022-0128","DOIUrl":"https://doi.org/10.2217/rme-2022-0128","url":null,"abstract":"<p><p>Abnormal craniofacial bone fusion can lead to the generation of several congenital malformations such as cleft palate, craniosynostosis and craniofacial skeletal hypoplasia, which physically and mentally affect patients. Conventional approaches for the treatment of craniofacial malformations such as the transplantation of autologous bone grafts are not completely efficient and usually, patients suffer from various complications. In line with these statements, the advent of novel therapeutic approaches in human medicine is mandatory. Regarding the extent, size and severity of the bone malformation, supplementation and release of oxygen molecules into the affected sites are critical issues for successful osteogenesis. Here, tissue engineering modalities associated with oxygen supplementation and novel approaches associated with hydrogel synthesis were highlighted in terms of craniofacial malformations.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 6","pages":"487-504"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9687810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gabriela Guaraldo Campos Totoli, Rayana Longo Bighetti-Trevisan, Gileade Pereira Freitas, Leticia Faustino Adolpho, Adriana Luisa Golçalves Almeida, Ana Carolina Loyola Barbosa, Jaqueline Isadora Reis Ramos, Marcio Mateus Beloti, Adalberto Luiz Rosa
Aim: We evaluated the bone repair induced by MSCs from adipose tissue (AT-MSCs) and bone marrow (BM-MSCs) injected into rat calvarial defects at two time points. Methods & results: Both cell populations expressed MSC surface markers and differentiated into adipocytes and osteoblasts. μCT showed that the combination of cells from distinct sources exhibited synergistic effects to increase bone repair with an advantage when BM-MSCs were injected prior to AT-MSCs. The higher osteogenic potential of these MSC combinations was demonstrated using an in vitro coculture system where BM-MSCs and AT-MSCs association induced higher ALP activity in MC3T3-E1 cells. Conclusion: Our findings may drive new approaches to treat bone defects and shed light on the complexity of the mechanisms involved in bone regeneration.
{"title":"Association of mesenchymal stem cells derived from bone marrow and adipose tissue enhances bone repair in rat calvarial defects.","authors":"Gabriela Guaraldo Campos Totoli, Rayana Longo Bighetti-Trevisan, Gileade Pereira Freitas, Leticia Faustino Adolpho, Adriana Luisa Golçalves Almeida, Ana Carolina Loyola Barbosa, Jaqueline Isadora Reis Ramos, Marcio Mateus Beloti, Adalberto Luiz Rosa","doi":"10.2217/rme-2022-0219","DOIUrl":"https://doi.org/10.2217/rme-2022-0219","url":null,"abstract":"<p><p><b>Aim:</b> We evaluated the bone repair induced by MSCs from adipose tissue (AT-MSCs) and bone marrow (BM-MSCs) injected into rat calvarial defects at two time points. <b>Methods & results:</b> Both cell populations expressed MSC surface markers and differentiated into adipocytes and osteoblasts. μCT showed that the combination of cells from distinct sources exhibited synergistic effects to increase bone repair with an advantage when BM-MSCs were injected prior to AT-MSCs. The higher osteogenic potential of these MSC combinations was demonstrated using an <i>in vitro</i> coculture system where BM-MSCs and AT-MSCs association induced higher ALP activity in MC3T3-E1 cells. <b>Conclusion:</b> Our findings may drive new approaches to treat bone defects and shed light on the complexity of the mechanisms involved in bone regeneration.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 5","pages":"377-387"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9651363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-05-11DOI: 10.2217/rme-2023-0057
Julie G Allickson
Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.
Julie G Allickson 博士是梅奥诊所(明尼苏达州、佛罗里达州和亚利桑那州)梅奥诊所再生生物治疗中心的迈克尔-S 和玛丽-苏-香农家族主任,也是再生生物治疗中心生物制造和产品开发奥托-布雷默信托主任。Allickson博士在再生医学、细胞疗法和监管事务方面拥有超过25年的经验,他领导该中心转向生物制造,确保新发现能够成功地应用于临床,并最终实现商业化。该中心正在组建一支行业经验丰富的团队,负责生物制造的所有支柱工作,为梅奥诊所的临床研究人员和主要研究人员提供支持。
{"title":"Expanding the manufacturing capacity for cell and gene therapies: an interview with Julie G Allickson.","authors":"Julie G Allickson","doi":"10.2217/rme-2023-0057","DOIUrl":"10.2217/rme-2023-0057","url":null,"abstract":"<p><p>Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 5","pages":"373-375"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9589387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hirotaka Nakagawa, Kyungje Sung, Ken Mautner, Tabitha May, Walter I Sussman
Aim: To evaluate the clinical response to augmenting ultrasound-guided tenotomy (USGT) with an amniotic membrane (AM) allograft injection. Design: Retrospective study. Materials & methods: Subjects underwent either a USGT (N = 16) or a combined USGT plus AM injection (N = 14). Results: Both groups demonstrated a significant reduction in pain from baseline starting after 2 weeks in the USGT plus AM group (p = 0.036) and after 8 weeks in the USGT group (p = 0.021). The reduction in pain was sustained for the entire duration of the study (52 weeks). There was no significant difference in pain levels at 26- or 52-week follow-up or patient satisfaction between the two groups. Conclusion: USGT with or without AM allograft injections results in a significant reduction in pain with high patient satisfaction.
{"title":"Lateral epicondylitis: comparing ultrasound-guided tenotomy with or without amniotic membrane allograft injection.","authors":"Hirotaka Nakagawa, Kyungje Sung, Ken Mautner, Tabitha May, Walter I Sussman","doi":"10.2217/rme-2023-0027","DOIUrl":"https://doi.org/10.2217/rme-2023-0027","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the clinical response to augmenting ultrasound-guided tenotomy (USGT) with an amniotic membrane (AM) allograft injection. <b>Design:</b> Retrospective study. <b>Materials & methods:</b> Subjects underwent either a USGT (N = 16) or a combined USGT plus AM injection (N = 14). <b>Results:</b> Both groups demonstrated a significant reduction in pain from baseline starting after 2 weeks in the USGT plus AM group (p = 0.036) and after 8 weeks in the USGT group (p = 0.021). The reduction in pain was sustained for the entire duration of the study (52 weeks). There was no significant difference in pain levels at 26- or 52-week follow-up or patient satisfaction between the two groups. <b>Conclusion:</b> USGT with or without AM allograft injections results in a significant reduction in pain with high patient satisfaction.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 5","pages":"399-411"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in January 2023.
根据公开信息和非学术机构新闻稿汇编的干细胞研究和再生医学领域的最新进展。
{"title":"Industry updates from the field of stem cell research and regenerative medicine in January 2023.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.2217/rme-2023-0045","DOIUrl":"https://doi.org/10.2217/rme-2023-0045","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in January 2023.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":"18 5","pages":"363-372"},"PeriodicalIF":2.7,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}